​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $194.09, with a high of $235.00 and a low of $144.00. This represents a 2.83% increase from the last price of $188.75.

- $50 $100 $150 $200 $250 High: $235 Avg: $194.09 Low: $144 Last Closed Price: $188.75

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 1 Strong Buy (4.35%), 21 Buy (91.30%), 1 Hold (4.35%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 1 21 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines2.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61332
Avg Price Target$211.35$196.16$157.50
Last Closing Price$188.75$188.75$188.75
Upside/Downside11.97%3.93%-16.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 264171--22
Jun, 264171--22
May, 26417---21
Apr, 26416---20
Mar, 26416---20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 23, 2026Robert DriscollWedbush$192.10$190.940.61%1.77%
Jul 09, 2026Michael SchmidtGuggenheim$235.00$189.7723.83%24.50%
Jul 06, 2026Mizuho Securities$215.00$190.5012.86%13.91%
Jul 02, 2026Wedbush$181.00$184.29-1.79%-4.11%
Jun 30, 2026Truist Financial$210.00$192.629.02%11.26%
Jun 29, 2026Ami FadiaNeedham$235.00$186.3926.08%24.50%
Jun 09, 2026Michael YeeUBS$175.00$148.4517.88%-7.28%
Jun 02, 2026Leonid TimashevRBC Capital$182.00$163.6811.19%-3.58%
Jun 01, 2026H.C. Wainwright$195.00$162.5119.99%3.31%
Jun 01, 2026Oppenheimer$195.00$157.4823.83%3.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2026WedbushOutperformOutperformhold
Jul 09, 2026GuggenheimBuyBuyhold
Jun 29, 2026NeedhamBuyBuyhold
Jun 22, 2026RBC CapitalOutperformOutperformhold
Jun 09, 2026UBSBuyBuyhold
Jun 02, 2026RBC CapitalOutperformOutperformhold
Jun 01, 2026H.C. WainwrightBuyBuyhold
Jun 01, 2026WedbushOutperformOutperformhold
Jun 01, 2026Cowen & Co.BuyBuyhold
Jun 01, 2026OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.08$-3.86$-3.58$-5.95---
Avg Forecast$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-1.20%-6.38%10.92%3.17%51.40%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.39M$35.38M$11.58M-----
Avg Forecast$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %2.11%26.98%-8.47%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.09M$-248.71M$-436.37M$-600.09M$-1.13B---
Avg Forecast$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %11.33%33.30%-44.83%140.93%---

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 21 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 23 Wall Street analysts, averages $194.09 over the next 12 months. The price target range spans from $144 at the low end to $235 at the high end, suggesting a potential 2.83% change from the previous closing price of $188.75.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 2.83% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • July 2026: 18.18% Strong Buy, 77.27% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 18.18% Strong Buy, 77.27% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 19.05% Strong Buy, 80.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.05, marking a -31.93% decrease from the reported $-5.95 in 2025. Estimates for the following years are $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $19.77M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $178.13M, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2026 stands at $-396M, representing a -64.96% decrease from the reported $-1.131B in 2025. Projections indicate $-609M in 2027, and $-187M in 2028.